4-hydroxybutyric acid analogs

Patent metadata

Field	Value
Publication number	US-10040748-B2
Application number	US-201615095545-A
Country	US
Kind code	B2
Filing date	Apr 11, 2016
Priority date	Feb 14, 2011
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

First claim

What is claimed is:

1. A pharmaceutical composition comprising an effective amount of a compound of formula IV-a:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein each position designated as deuterium has a deuterium incorporation of at least 75%.

2. The pharmaceutical composition of claim 1 , additionally comprising a second therapeutic agent which is a dual serotonin-norepinephrine reuptake inhibitor or an alpha2-delta subunit calcium channel modulator.

3. The pharmaceutical composition of claim 2 , wherein the second therapeutic agent is duloxetine, milnacipran, venlafaxine, pregabalin, gabapentin, or a prodrug thereof.

4. The pharmaceutical composition of claim 1 , wherein each position designated as deuterium has a deuterium incorporation of at least 82.5%.

5. The pharmaceutical composition of claim 1 , wherein each position designated as deuterium has a deuterium incorporation of at least 90%.

6. The pharmaceutical composition of claim 1 , wherein each position designated as deuterium has a deuterium incorporation of at least 95%.

7. The pharmaceutical composition of claim 1 , wherein each position designated as deuterium has a deuterium incorporation of at least 97%.

8. A method of treating a disease or disorder selected from narcolepsy, excessive daytime sleepiness (EDS), or cataplexy, comprising the step of administering to a patient in need thereof an effective amount of a composition of claim 1 .

9. The method of claim 8 , wherein the disease or disorder is narcolepsy with cataplexy.

10. The method of claim 8 , wherein each position designated as deuterium has a deuterium incorporation of at least 82.5%.

11. The method of claim 8 , wherein each position designated as deuterium has a deuterium incorporation of at least 90%.

12. The method of claim 8 , wherein each position designated as deuterium has a deuterium incorporation of at least 95%.

13. The method of claim 8 , wherein each position designated as deuterium has a deuterium incorporation of at least 97%.

Assignees

• Concert Pharmaceuticals Inc

Inventors

• Tung Roger D
• Morgan Adam J

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/32

  Alcohol-abuse · CPC title

• A61P25/30

  for treating abuse or dependence · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title